Michael B. Dwinell, PhD

Professor; Founding Director, Center for Immunology; Director, Bobbie Nick Voss Laboratory for Colon Cancer Research; Leader, Molecular Cancer Therapeutics

Locations

Microbiology & Immunology
TBRC C3860

Contact Information

General Interests

Inflammation and Immunology, Cancer Biology

Education

PhD, GI Pathophysiology, University of Wisconsin, Madison, 1996

Research Experience

Carcinoma
Carcinoma, Pancreatic Ductal
Cell Line, Tumor
Cell Movement
Cell Proliferation
Chemokine CXCL12
Chemokines
Chemokines, CC
Chemokines, CXC
Cytokines
Defensins
Energy Metabolism

Research Interests

Dwinell Laboratory: Bobbie Nick Voss Laboratory for Colon Cancer Research

Research in the Dwinell laboratory seeks to define the role for extracellular mediators in the progression and metastasis of solid and hematological cancers. Additional studies are examining the role for metabolic reprogramming to influence tumor progression and exploring new mitochondria-targeted compounds as inhibitors of cancer progression. Human and murine 2D and 3D cell culture systems and preclinical models are being used to investigate the cellular, biochemical, and metabolic signaling pathways that regulate cellular proliferation, programmed cell death and motility in inflammation and cancer. Pharmacokinetic / pharmacodynamics, toxicity and potency / efficacy studies following treatment with small molecule or biologic compounds are also being completed. These translational research studies are multidisciplinary and include molecular cloning, cell culture, biochemical assays and signal processing, histopathology, flow cytometry, and small animal imaging and handling. Completion of these studies will strengthen our identification of new targets for therapeutic intervention to improve human health.to improve human health. There are currently two major research directions in the laboratory.

Research in the Dwinell laboratory is supported through grants from the National Institutes of Health, the Medical College of Wisconsin Cancer Center and philanthropic donations.

Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators.

(Cheng G, Zielonka J, Hardy M, Ouari O, Chitambar CR, Dwinell MB, Kalyanaraman B.) Oncotarget. 2019 May 28;10(37):3518-3532 PMID: 31191823 PMCID: PMC6544408 06/14/2019
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.

(Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB.) J Immunother Cancer. 2019 Apr 29;7(1):115 PMID: 31036082 PMCID: PMC6489306 SCOPUS ID: 2-s2.0-85065258266 05/01/2019
A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis.

(Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA.) Cancer Epidemiol Biomarkers Prev. 2019 04;28(4):680-689 PMID: 30530849 PMCID: PMC6545232 SCOPUS ID: 2-s2.0-85063867816 12/12/2018
Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation.

(Boyle KA, Van Wickle J, Hill RB, Marchese A, Kalyanaraman B, Dwinell MB.) J Biol Chem. 2018 09 21;293(38):14891-14904 PMID: 30087121 PMCID: PMC6153299 SCOPUS ID: 2-s2.0-85054023214 08/09/2018
Corrigendum to 'A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds' [REDOX 14C (2017) 316-327].

(Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 06;16:426-427 PMID: 29548725 PMCID: PMC5952812 SCOPUS ID: 2-s2.0-85043469209 03/20/2018
Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.

(Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ.) Immunohorizons. 2018 Apr 01;2(4):107-118 PMID: 30027154 PMCID: PMC6048965 07/22/2018
A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds.

(Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 04;14:316-327 PMID: 29017115 PMCID: PMC5633086 SCOPUS ID: 2-s2.0-85030681499 10/11/2017
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

(Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335 PMID: 29587663 PMCID: PMC5870823 SCOPUS ID: 2-s2.0-85044523365 03/29/2018
GEMMs Are a Gem When it Comes to Defining the Role of HIF2α in Mucinous Cystic Neoplasms.

(Boyle KA, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2018;5(2):165-166 PMID: 29693045 PMCID: PMC5904046 SCOPUS ID: 2-s2.0-85039848766 04/26/2018
Differences in Sulfotyrosine Binding amongst CXCR1 and CXCR2 Chemokine Ligands.

(Moussouras NA, Getschman AE, Lackner ER, Veldkamp CT, Dwinell MB, Volkman BF.) Int J Mol Sci. 2017 Sep 03;18(9) PMID: 28869519 PMCID: PMC5618543 SCOPUS ID: 2-s2.0-85028764300 09/05/2017
CCR7 Sulfotyrosine Enhances CCL21 Binding.

(Phillips AJ, Taleski D, Koplinski CA, Getschman AE, Moussouras NA, Richard AM, Peterson FC, Dwinell MB, Volkman BF, Payne RJ, Veldkamp CT.) Int J Mol Sci. 2017 Aug 25;18(9) PMID: 28841151 PMCID: PMC5618506 SCOPUS ID: 2-s2.0-85028343200 08/26/2017
Stromal inflammation in pancreatic cancer: Mechanisms and translational applications

(Boyle KA, James MA, Tsai S, Evans DB, Dwinell MB.) Pancreatic Cancer. 11 April 2018:481-508 SCOPUS ID: 2-s2.0-85054043119 04/11/2018

Michael B. Dwinell, PhD